Vortioxetine for treating major depressive episodes

  • Technology appraisal guidance
  • TA367
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the committee

A. The evidence review group (ERG) report for this appraisal was prepared by CRD and CHE Technology Assessment Group, University of York:

  • Simmonds M, Lomas J, Llewellyn A et al. Vortioxetine for treating major depressive disorder, April 2015

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Lundbeck

II. Professional/expert and patient/carer groups:

  • Black Mental Health UK

  • British Association for Psychotherapy

  • College of Mental Health Pharmacy

  • Depression Alliance

  • Royal College of Psychiatrists

III. Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Cochrane Depression and Anxiety Group

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Health Improvement Scotland

  • Merck Serono

  • MRC Clinical Trials Unit

  • Servier

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on vortioxetine by attending the initial committee discussion and providing a written statement to the committee. They were also invited to comment on the ACD.

  • Professor Heinz Grunze, Professor of Clinical Psychiatry, Academic Psychiatry and Regional Affective Disorders Service

  • Newcastle University, nominated by Lundbeck – clinical expert

  • Emer O'Neill, Chief Executive, Depression Alliance, nominated by Depression Alliance – patient expert

D. Representatives from the following company attended committee meetings. They contributed only when asked by the committee chair to clarify specific issues and comment on factual accuracy.

  • Lundbeck

ISBN: 978-1-4731-1555-2